Logo

Boehringer Ingelheim's Ofev (nintedanib) as the First Treatment for Chronic Fibrosing ILDs with Progressive Phenotype

Share this

Boehringer Ingelheim's Ofev (nintedanib) as the First Treatment for Chronic Fibrosing ILDs with Progressive Phenotype

Shots:

  • The FDA’s approval is based on P-III INBUILD study assessing Ofev (150mg- bid) vs PBO in 663 patients with chronic fibrosing ILDs with a progressive phenotype for 52wks. at 153 sites across 15 countries
  • The P-III INBUILD study results demonstrated that therapy slowed the loss of pulmonary function by 57% (107ml/yr.) across a range of patients while in patients with IP-like fibrotic pattern on HRCT- Ofev slowed the loss of pulmonary function by 61% (128.2ml/yr.)
  • Ofev is a tyrosine kinase inhibitor- approved in 75+ countries for IPF and has received the US FDA’s approval as the first therapy to slow the rate of decline in pulmonary function in patients with SSc-ILD in Sept’2019

Click here ­to­ read full press release/ article | Ref: Boehringer Ingelheim  | Image: News-Times


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions